drugset / Trial / NCT01958645

To Assess Safety, Tolerability and Pharmacodynamics of Intravenous MEDI8111 After Single Ascending Doses.

NCT01958645 ↗

Phase 1 Completed 157 enrolled AstraZeneca
RandomizedParallel-groupSingle-blindBasic science

Summary

A study to investigate the safety, tolerability and pharmacodynamics of MEDI8111 after single ascending doses in healthy male.

Timeline

Start
2013-11
Primary completion
2014-10
Completion
2014-10

Drugs

EvaluationDrugModalityDoseRoute
Subject MEDI8111 Unknown — Intravenous

Indications

No indication recorded.